2024
Characterization of time toxicity in older patients with metastatic breast cancer
Atre S, Soulos P, Kuderer N, Gross C, Baum L, Dinan M, Lustberg M. Characterization of time toxicity in older patients with metastatic breast cancer. Breast Cancer Research And Treatment 2024, 207: 541-550. PMID: 38816556, DOI: 10.1007/s10549-024-07379-7.Peer-Reviewed Original ResearchMetastatic breast cancerBone-modifying agentsComorbid medical conditionsOlder patientsBreast cancerRetrospective cohort studySEER-Medicare databaseTreatment typeCancer treatment modalityTreatment modalitiesSEER-MedicareCohort studyUnadjusted analysisPatientsAge-related impactCancer treatmentComorbiditiesDay patientsCancerRadiotherapyOlder ageMedical conditionsToxicityTreatmentSociodemographic factors
2023
Falls and hospitalization during chemotherapy in older women with early breast cancer.
Ji J, Sun C, Wildes T, Freedman R, Magnuson A, O'Connor T, Moy B, Klepin H, Chapman A, Tew W, Dotan E, Fenton M, Kim H, Bae M, Katheria V, Gross C, Muss H, Cohen H, Sedrak M. Falls and hospitalization during chemotherapy in older women with early breast cancer. Journal Of Clinical Oncology 2023, 41: 12035-12035. DOI: 10.1200/jco.2023.41.16_suppl.12035.Peer-Reviewed Original ResearchRisk of hospitalizationEarly breast cancerFall historyBreast cancerOlder adultsOlder womenStage II/III diseaseProspective multicenter studyMultivariable logistic regressionSelf-reported fall historyAdjuvant chemoCommon toxicitiesFebrile neutropeniaPrimary endpointPrimary prophylaxisGeriatric assessmentOlder patientsClinical factorsMedian ageAvoidable complicationsMulticenter studyClinical covariatesTreatment decisionsHospitalizationWomen's ageAssociation Between Age and Survival Trends in Advanced Non–Small Cell Lung Cancer After Adoption of Immunotherapy
Voruganti T, Soulos P, Mamtani R, Presley C, Gross C. Association Between Age and Survival Trends in Advanced Non–Small Cell Lung Cancer After Adoption of Immunotherapy. JAMA Oncology 2023, 9: 334-341. PMID: 36701150, PMCID: PMC9880865, DOI: 10.1001/jamaoncol.2022.6901.Peer-Reviewed Original ResearchConceptsAdvanced non-small cell lung cancerNon-small cell lung cancerImmune checkpoint inhibitorsUse of ICIsPatients 75 yearsCell lung cancerDrug Administration approvalCohort studyOlder patientsLung cancerAdministration approvalUS FoodAdoption of immunotherapyMedian overall survivalCancer-directed therapySubstantial survival benefitFirst US FoodCheckpoint inhibitorsStage IIIBClinical characteristicsICI useMedian survivalOverall survivalSurvival benefitSurvival gainEvolution of systemic therapy from 2015 to 2019 for older patients in the United States with metastatic renal cell carcinoma.
Chow R, Long J, Hassan S, Wheeler S, Spees L, Leapman M, Hurwitz M, McManus H, Gross C, Dinan M. Evolution of systemic therapy from 2015 to 2019 for older patients in the United States with metastatic renal cell carcinoma. Journal Of Clinical Oncology 2023, 41: 610-610. DOI: 10.1200/jco.2023.41.6_suppl.610.Peer-Reviewed Original ResearchMetastatic renal cell carcinomaImmune checkpoint inhibitorsOral anti-cancer agentsNon-Hispanic white patientsSystemic therapyRenal cell carcinomaNHW patientsWhite patientsCell carcinomaMedicare beneficiariesService Medicare Parts ARetrospective cohort studyOverall treatment rateMedicare Part AIO therapyMRCC therapyAnti-cancer agentsCheckpoint inhibitorsCohort studyOlder patientsRandomized trialsSurvival improvementFirst therapyStudy criteriaTreatment receipt
2022
Low-Intensity Adjuvant Chemotherapy for Breast Cancer in Older Women: Results From the Prospective Multicenter HOPE Trial
Sedrak M, Sun C, Ji J, Cohen H, Gross C, Tew W, Klepin H, Wildes T, Dotan E, Freedman R, O'Connor T, Chow S, Fenton M, Moy B, Chapman A, Dale W, Katheria V, Kuderer N, Lyman G, Magnuson A, Muss H. Low-Intensity Adjuvant Chemotherapy for Breast Cancer in Older Women: Results From the Prospective Multicenter HOPE Trial. Journal Of Clinical Oncology 2022, 41: 316-326. PMID: 36455189, PMCID: PMC9839299, DOI: 10.1200/jco.22.01440.Peer-Reviewed Original ResearchConceptsLow relative dose intensityRelative dose intensityAdjuvant chemotherapyHOPE trialDose intensityOlder patientsOlder womenBreast cancer benefitPrespecified secondary analysisCurative-intent treatmentInferior survival outcomesChemotherapy dose intensityKaplan-Meier methodLow performance statusMultivariable logistic regressionLog-rank testOverall survival probabilityToxic side effectsCancer benefitOverall survivalPerformance statusStandard chemotherapySupportive carePrimary outcomeSurvival outcomesEnd-of-Life Care for Patients With Metastatic Renal Cell Carcinoma in the Era of Oral Anticancer Therapy
Dzimitrowicz H, Wilson L, Jackson B, Spees L, Baggett C, Greiner M, Kaye D, Zhang T, George D, Scales C, Pritchard J, Leapman M, Gross C, Dinan M, Wheeler S. End-of-Life Care for Patients With Metastatic Renal Cell Carcinoma in the Era of Oral Anticancer Therapy. JCO Oncology Practice 2022, 19: e213-e227. PMID: 36413741, PMCID: PMC9970274, DOI: 10.1200/op.22.00401.Peer-Reviewed Original ResearchConceptsMetastatic renal cell carcinomaOral anticancer agentsDays of lifeRenal cell carcinomaEOL careSystemic therapySEER-MedicareHospital deathCell carcinomaLife careIntensive care unit admissionCancer informationAggressive EOL careHigh-quality EOLOral anticancer therapySystemic therapy useCare unit admissionMultivariable logistic regressionQuality of endUnit admissionED visitsOlder patientsYounger patientsHospital admissionTherapy useFactors associated with the quality of end-of-life care for patients with metastatic renal cell carcinoma.
Dzimitrowicz H, Wilson L, Jackson B, Spees L, Baggett C, Greiner M, Kaye D, Zhang T, George D, Scales C, Pritchard J, Leapman M, Gross C, Dinan M, Wheeler S. Factors associated with the quality of end-of-life care for patients with metastatic renal cell carcinoma. Journal Of Clinical Oncology 2022, 40: 300-300. DOI: 10.1200/jco.2022.40.6_suppl.300.Peer-Reviewed Original ResearchMetastatic renal cell carcinomaOral anti-cancer agentsRenal cell carcinomaSEER-MedicareDays of lifeSystemic therapyICU admissionCell carcinomaOdds ratioLife careSEER-Medicare cohortSystemic therapy useMultivariable logistic regressionUse of hospiceQuality of endHigh-quality endMRCC diagnosisAnti-cancer agentsMost patientsOlder patientsHospital admissionMedian ageTherapy useImmunotherapy treatmentRetrospective study
2017
Impact of hearing and visual impairment in older adults with cancer.
Soto Perez De Celis E, Sun C, Tew W, Mohile S, Gajra A, Klepin H, Owusu C, Gross C, Muss H, Lichtman S, Chapman A, Cohen H, Dale W, Kim H, Katheria V, Hurria A. Impact of hearing and visual impairment in older adults with cancer. Journal Of Clinical Oncology 2017, 35: 10036-10036. DOI: 10.1200/jco.2017.35.15_suppl.10036.Peer-Reviewed Original ResearchCognitive deficitsOlder adultsImpact of hearingVisual impairmentIADL dependencyImpaired hearingAnxietyDaily livingDeficitsInstrumental activitiesImpairmentDepressionHearingCross-sectional analysisAdultsChemotherapy toxicityOlder patientsProspective studyRisk factorsADL limitationsHigh riskSolid tumorsMultivariate analysisCancerRiskAdoption of immunotherapy into real-world practice: Insights from the use of checkpoint inhibitors.
O'Connor J, Seidl-Rathkopf K, You P, Nussbaum N, Torres A, Fessele K, Darius K, Adelson K, Yin E, Presley C, Chiang A, Ross J, Abernethy A, Gross C. Adoption of immunotherapy into real-world practice: Insights from the use of checkpoint inhibitors. Journal Of Clinical Oncology 2017, 35: e14583-e14583. DOI: 10.1200/jco.2017.35.15_suppl.e14583.Peer-Reviewed Original ResearchElectronic health record databaseReal-world practiceCheckpoint inhibitorsAdvanced non-small cell lung cancerFDA approvalNon-small cell lung cancerDeath-1 checkpoint inhibitorsMetastatic renal cell carcinomaAdoption of immunotherapyGeneralizability of trialsCell lung cancerRenal cell carcinomaDrug Administration approvalHealth record databaseChi-square testStudy drugOlder patientsSystemic therapyAdvanced melanomaMedian ageTherapy linesCell carcinomaLung cancerAdministration approvalClinical trials
2012
The relations between age and androgen deprivation therapy use among men receiving radiation therapy for prostate cancer in the Medicare population.
Quon J, Yu J, Soulos P, Gross C. The relations between age and androgen deprivation therapy use among men receiving radiation therapy for prostate cancer in the Medicare population. Journal Of Clinical Oncology 2012, 30: e15150-e15150. DOI: 10.1200/jco.2012.30.15_suppl.e15150.Peer-Reviewed Original ResearchHigh-risk groupShort life expectancyRisk groupsProstate cancerLife expectancyNational Comprehensive Cancer Network guidelinesAndrogen deprivation therapy useConcurrent androgen deprivation therapyEnd Results-Medicare databaseAndrogen deprivation therapyLow-risk cancersExternal beam radiationLow-risk groupLonger life expectancyDeprivation therapyNCCN guidelinesOlder patientsClinical factorsTherapy useGuideline recommendationsTumor characteristicsNetwork guidelinesCancer characteristicsRadiation therapyMedicare population
2009
Geriatric assessment of older adults with cancer: Baseline data from a 500 patient multicenter study
Hurria A, Mohile S, Lichtman S, Owusu C, Klepin H, Gross C, Hansen K, Klapper S, Togawa K, Tew W. Geriatric assessment of older adults with cancer: Baseline data from a 500 patient multicenter study. Journal Of Clinical Oncology 2009, 27: 9546-9546. DOI: 10.1200/jco.2009.27.15_suppl.9546.Peer-Reviewed Original ResearchGeriatric assessmentOlder adultsBrief geriatric assessmentNew chemotherapy regimenStage IV diseaseComorbid medical conditionsMultivariate logistic regressionCommon tumor typesNon-white raceGross cognitive impairmentBlessed Orientation-MemoryChemotherapy regimenChemotherapy toxicityMetastatic diseaseOlder patientsPatient ageMulticenter studyFunctional statusProspective dataOncology practiceTreatment decisionsInstrumental activitiesMedical conditionsGYN cancersHigh school education
2004
838-1 National patterns of spironolactone prescription for older patients with heart failure and left ventricular systolic dysfunction before and after RALES
Masoudi F, Gross C, Wang Y, Havranek E, Rathore S, Foody J, Krumholz H. 838-1 National patterns of spironolactone prescription for older patients with heart failure and left ventricular systolic dysfunction before and after RALES. Journal Of The American College Of Cardiology 2004, 43: a415. DOI: 10.1016/s0735-1097(04)91750-0.Peer-Reviewed Original Research